Financial Performance - Revenue for the current period reached ¥132,309,174.89, representing a 17.90% increase compared to ¥112,225,810.15 in the same period last year[13]. - Net profit attributable to shareholders was ¥13,847,503.44, a 35.15% increase from ¥10,245,890.81 year-over-year[13]. - The company's gross profit margin improved to 20.82%, up from 18.13% in the previous year[13]. - The company achieved operating revenue of 132.31 million yuan, a year-on-year increase of 17.90%[23]. - Net profit attributable to shareholders of the parent company was 13.85 million yuan, up 35.15% year-on-year[23]. - The new product NHDC saw a sales volume increase of 964.27% and a sales revenue increase of 1,545.79% compared to the previous year[23]. - Operating profit rose to ¥17,222,089.91, a 64.01% increase from ¥10,500,803.71 in the previous year[30]. - Net profit for the period was ¥13,625,149.63, representing a year-on-year increase of 32.98% from ¥10,245,890.81[30]. - The company reported a significant increase in other income, which rose by 80.07% to ¥1,350,636.50 due to increased government subsidies[30]. - The total comprehensive income for the first half of 2024 is 14,869,375.80 CNY, compared to 10,309,290.19 CNY in the same period of 2023, showing an increase of 44.88%[73]. Assets and Liabilities - Total assets decreased by 4.34% to ¥433,430,452.40 from ¥453,093,129.65 at the end of the previous year[14]. - Total liabilities decreased significantly by 34.52% to ¥39,105,174.46 from ¥59,718,298.80 year-over-year[14]. - Total assets at the end of the reporting period were 433.43 million yuan, a decrease of 4.34% from the beginning of the period[23]. - Total liabilities decreased by 34.52% to 39.11 million yuan compared to the beginning of the period[23]. - The company's cash and cash equivalents decreased by 73.34% to ¥13.73 million, primarily due to investments in ongoing projects[28]. - The company's accounts payable decreased by 73.66% to ¥8.13 million, mainly due to payments for previous purchases[29]. - The company's total current assets decreased from ¥294,402,629.11 to ¥221,065,379.80, a decline of approximately 25%[64]. - Total non-current assets increased from ¥158,690,500.54 to ¥212,365,072.60, an increase of approximately 34%[65]. - The total amount of receivables at the end of the period was 66,217,781.83, an increase from 65,111,132.38 at the beginning of the period, reflecting a growth of about 1.7%[166]. Cash Flow - The company reported a net cash flow from operating activities of -¥22,696,438.30, a decline of 170.60% compared to ¥32,148,479.36 in the same period last year[16]. - Cash inflow from operating activities for the first half of 2024 is 149,594,186.04 CNY, down from 157,890,673.48 CNY in the first half of 2023, a decline of 5.67%[75]. - The total cash and cash equivalents at the end of the period was 8,593,633.98 yuan, significantly down from 118,342,060.13 yuan at the end of the previous year[78]. - The total cash at the end of the period is RMB 13,734,086.77, down from RMB 51,521,096.61 at the beginning of the period[160]. Research and Development - The company has established a joint laboratory with the Chinese Academy of Sciences and collaborates with universities for research and development[21]. - The company has a total of 6 invention patents and 31 utility model patents, reflecting its strong focus on innovation in the plant extraction field[21]. - Research and development expenses decreased by 39.65% to ¥4,408,237.31, down from ¥7,304,498.51 in the previous year[30]. - The company is committed to innovation-driven development and the transformation of R&D achievements into production and sales[25]. - The successful development of water-soluble Quercetin addresses the technical challenge of its solubility, potentially opening new market opportunities[48]. Market Expansion and Strategy - The company aims to expand its market presence in North America and Europe, supported by compliance with international quality standards such as FDA[21]. - The company is focusing on cost reduction and efficiency improvement to enhance product market competitiveness[25]. - The company is actively participating in domestic and international exhibitions to promote new product registrations and market expansion[25]. - The company is focusing on developing new markets and has accelerated the development of domestic raw materials and functional food ingredients[46]. - The company is prepared to face potential increases in environmental protection costs due to stricter regulations[46]. Shareholder and Capital Structure - The total number of ordinary shares is 75,631,404, with 25.00% being unrestricted shares and 75.00% being restricted shares[52]. - The largest shareholder, Zhao Zhuojun, holds 31,178,881 shares, representing 41.22% of the total shares[53]. - The company raised a total of RMB 231,500,556.80 from its public offering, with a net amount of RMB 212,317,682.73 after deducting issuance costs[55]. - The company has maintained a stable management structure with no changes in the chairman or general manager[60]. - The company has not issued any preferred shares or convertible bonds during the reporting period[56]. Compliance and Social Responsibility - The company has established an EHS management system to ensure compliance with environmental regulations and has obtained a pollution discharge permit valid until December 21, 2025[42]. - The company donated 20,000 yuan to a charity for elderly care, reflecting its commitment to social responsibility[41]. - The company has obtained 8 SC certificates, enabling product sales in the domestic market and meeting overseas market entry requirements[45]. - The company has passed FDA inspections, providing strong quality assurance for expanding into the US market[45]. Risks and Challenges - The company faces risks related to the inability to digest production capacity and asset impairment, which could negatively impact overall business performance[47]. - The company is at risk of losing market share if domestic raw material prices rise, leading to a shift towards Brazilian suppliers for Quercetin[48]. - There are no significant changes in major risks compared to the previous period, indicating stability in risk management[48]. Employee and Management - The total number of employees at the end of the period is 199, a decrease of 10 from the beginning of the period[63]. - The management team increased from 17 to 18 employees, while production personnel decreased from 131 to 120[63]. - The company has maintained a total of 89 employees during the reporting period[200].
欧康医药(833230) - 2024 Q2 - 季度财报